在被诊断患有耐火性的患者中, levetiracetam 的人口药理动力学:现实世界的研究
Rui Silva1,2, Helena Colom3,4, Anabela Almeida2,5
1Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
Epilepsia
|February 11, 2025
概括
这项研究开发了一种人群药理动力学模型,用于在耐火性患者中使用 levetiracetam. 经过验证的模型优化了剂量,提高了 levetiracetam 的有效性和安全性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 药学指标 (Pharmacometrics) 是一个指标.
背景情况:
- 莱维他是一种关键的抗发作药物,用于耐火性.
- 优化 levetiracetam 剂量对于患者的治疗结果至关重要.
研究的目的:
- 开发和验证一个人群药理动力学 (PopPK) 模型为 levetiracetam.
- 为了实现个性化的 levetiracetam 剂量策略在耐火性.
主要方法:
- 非线性混合效应建模使用了来自135名患者的256个 levetiracetam 度.
- 模型评估包括良性合适图,引导重新抽样和视觉预测检查 (VPC).
- 外部验证使用了另外37名患者的60个度.
主要成果:
- 一个具有第一阶排泄的单间模型最好地描述了 levetiracetam 药理动力学.
- 估计了关键的药理动力学参数 (CL/F,Vd/F,ka).
- 影响清除的共同变量包括同时服用抗发作药物,GFR和体重;受影响的身体表面积 Vd/F.
结论:
- 建立了一种可靠且经过验证的 levetiracetam PopPK 模型.
- 这个模型可以作为优化 levetiracetam 剂量方案的工具.
- 该模型支持增强成年耐药患者的药物有效性和安全性.
相关概念视频
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
216
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
216
01:20Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140
01:12Analysis of Population Pharmacokinetic Data
218
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
218
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
72
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
72
01:24Arteries of the Lower Limbs
177
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
177
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
310
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
310